Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Moist wound dressing for chronic wound treatment now available in Germany
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Subscribe To Our Newsletter & Stay Updated
